Spain introduces Safe Gambling Program 2026–2030 with 24 measures targeting player protection, youth safety, and evidence-based regulation.
Browsing: News
Kalshi offers $1 billion for perfect NCAA bracket predictions while navigating trademark restrictions and leading all sports betting brands in ad visibility.
SEC approves Nasdaq’s pilot to trade tokenized stocks on blockchain. Russell 1000 stocks and select ETFs can now trade as tokens with same rights as traditional shares.
Wisconsin’s sports betting bill awaits Gov. Evers’ signature. A 60% tribal revenue requirement may discourage DraftKings and FanDuel from participation.
Solana (SOL) rallies 22% after SEC-CFTC classify it as digital commodity. ETF inflows surge past $17M daily. Key price levels and technical outlook analyzed.
Brazil’s Bill 1172/2026 seeks to prohibit all digital gambling advertising across social platforms, apps, and websites. Find out what’s at stake.
Evernorth Holdings files for $1B+ Nasdaq listing as XRP gains commodity status. Analysis of XRPN merger, regulatory clarity, and price targets ahead.
Arizona filed 20 criminal counts against prediction market Kalshi for alleged illegal gambling. CEO Tarek Mansour and CFTC push back, calling it jurisdictional.
Polymarket acquires DeFi infrastructure startup Brahma to enhance its blockchain capabilities. Brahma products to close in 30 days amid $20B valuation talks.
Ethereum trades at $2,160 after $385M in ETF inflows and BlackRock’s staked ETH fund launch. Analyzing support levels and institutional momentum.
The Federal Reserve held interest rates steady at 3.50%-3.75% on March 18, citing Iran conflict uncertainty. Bitcoin fell 4% while stocks declined.
Bitcoin fell below $70K after the Fed held rates and projected only one 2026 cut. Oil surged past $110, adding pressure on risk assets like BTC.
Detailed 2026 comparison of Cloudbet vs ZunaBet crypto casinos. Discover which platform offers better games, bonuses, crypto support, and loyalty rewards.
Red Cat (RCAT) stock jumps 12% ahead of Q4 earnings, with revenue projected to soar 1,842% YoY to $26.5M on strong military drone contract demand.
AbbVie (ABBV) dropped 4.69% after FDA approved J&J’s Icotyde psoriasis treatment, creating new competition for blockbuster drug Skyrizi.